Population aging is associated with an increase in the number of sufferers of Alzheimer’s disease (AD), which in turn leads to a corresponding growth in the costs of caring for these persons. We do not currently possess sufficient knowledge concerning the biological sign markers which would allow us to better prevent and delay the effects of AD. Scientific researchers are unanimous, and have validated that olfactory identification is a reliable biomarker in the illnesses’ preclinical phase, or light dementia phase. Olfactory disorder has been accepted as a forerunning sign of the evolution of light cognitive decline into AD, as precisely as any other biological marker. However, the studies highlighting this association have also made evident that there exist no benchmark or absolute reference in olfactory study, specifically for the detection of Alzheimer’s disease, and that memory clinics only rarely make use of these in their clinical practice. The benchmarking and validation of a test conceived following the recommendations of memory clinic professionals are necessary.